China Pharma Holdings (CPHI) Debt to Equity (2016 - 2025)
China Pharma Holdings filings provide 16 years of Debt to Equity readings, the most recent being $0.09 for Q4 2025.
- On a quarterly basis, Debt to Equity fell 73.44% to $0.09 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.09, a 73.44% decrease, with the full-year FY2025 number at $0.09, down 73.44% from a year prior.
- Debt to Equity hit $0.09 in Q4 2025 for China Pharma Holdings, down from $0.24 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.62 in Q3 2022 to a low of $0.09 in Q4 2025.
- Median Debt to Equity over the past 5 years was $0.41 (2021), compared with a mean of $0.53.
- Biggest five-year swings in Debt to Equity: soared 119.86% in 2021 and later tumbled 75.68% in 2023.
- China Pharma Holdings' Debt to Equity stood at $0.72 in 2021, then decreased by 20.9% to $0.57 in 2022, then crashed by 42.41% to $0.33 in 2023, then fell by 0.1% to $0.33 in 2024, then tumbled by 73.44% to $0.09 in 2025.
- The last three reported values for Debt to Equity were $0.09 (Q4 2025), $0.24 (Q3 2025), and $0.42 (Q2 2025) per Business Quant data.